Search results
Results from the WOW.Com Content Network
Ketamine’s antidepressant effects are part of what prompted researchers to explore other drugs that target glutamate—like the venerable cough suppressant dextromethorphan found in Robitussin ...
Ketamine-assisted psychotherapy (KAP) is the use of prescribed doses of ketamine as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety, obsessive–compulsive disorders (OCD), post-traumatic stress disorders (PTSD), and other conditions. [1]
Unlike traditional antidepressants that target the neurotransmitters serotonin and/or norepinephrine, ketamine targets glutamate — the most abundant chemical messenger in the brain, Feifel said.
Esketamine, sold under the brand name Spravato and produced by Janssen Pharmaceuticals, was approved by the FDA in March 2019 for the treatment of Treatment-Resistant Depression (TRD) and suicidal ideation. [8] As of 2022, it is the only psychoplastogen approved in the US for the treatment of a neuropsychiatric disorder. [6]
The antidepressant effect of ketamine is diminished at 7 days, and most people relapse within 10 days. However, for a significant minority, the improvement may last 30 days or more. [25] [26] [59] [61] One of the main challenges with ketamine treatment can be the length of time that the antidepressant effects last after finishing a course of ...
Current ketamine treatment is in the form of a nasal spray (in the form of esketamine) or injection. Both require that the patient stays in the clinic to be monitored for around 2 hours. This ...
Cannabinoids, or cannabinoid receptor modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted psychotherapy or short-term use only. This list was last comprehensively updated in October 2024. It is likely to become outdated with time.
A slightly different version of ketamine, called esketamine or Spravato, was approved by the FDA in 2019 for treatment-resistant depression. Esketamine is given as a nasal spray and must be ...